PANACEA BIOTECH 2017-18 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on 21st October 2019, due to Assembly Elections in Maharashtra.

PANACEA BIOTECH 2017-18 Annual Report Analysis
Wed, 27 Mar

PANACEA BIOTECH has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

PANACEA BIOTECH Income Statement Analysis

  • Operating income during the year rose 9.0% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 35.4% YoY during the fiscal. Operating profit margins witnessed a fall and down at 14.3% in FY18 as against 11.5% in FY17.
  • Depreciation charges decreased by 13.9% and finance costs decreased by 0.3% YoY, respectively.
  • Other income declined by 82.3% YoY.
  • Net profit for the year grew by 85.9% YoY.
  • Net profit margins during the year declined from 6.9% in FY17 to 12.6% in FY18.

PANACEA BIOTECH Income Statement 2017-18

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
Net SalesRs m5,4405,9289.0%
Other incomeRs m46682-82.3%
Total RevenuesRs m5,9066,0101.8%
Gross profitRs m62484535.4%
DepreciationRs m680585-13.9%
InterestRs m1,0091,006-0.3%
Profit before taxRs m-599-66410.8%
TaxRs m-11099-189.8%
Profit after taxRs m-409-76085.9%
Gross profit margin%11.514.3
Effective tax rate%18.3-14.9
Net profit margin%-6.9-12.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



PANACEA BIOTECH Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 7 billion as compared to Rs 6 billion in FY17, thereby witnessing an increase of 17.5%.
  • Long-term debt down at Rs 6 billion as compared to Rs 7 billion during FY17, a fall of 20.1%.
  • Current assets rose 5% and stood at Rs 6 billion, while fixed assets fell 4% and stood at Rs 10 billion in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 16 billion as against Rs 18 billion during FY17, thereby witnessing a fall of 11%.

PANACEA BIOTECH Balance Sheet as on March 2018

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
NetworthRs m3,5573,087-13.2
 
Current LiabilitiesRs m5,8816,91017.5
Long-term DebtRs m7,1415,707-20.1
Total LiabilitiesRs m18,00116,076-10.7
 
Current assetsRs m5,3345,6035.0
Fixed AssetsRs m 10,3689,941-4.1
Total AssetsRs m18,00116,076-10.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



PANACEA BIOTECH Cash Flow Statement Analysis

  • PANACEA BIOTECH's cash flow from operating activities (CFO) during FY18 stood at Rs 1 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs 553 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs -2 billion on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs 90 million from the Rs -21 million net cash flows seen during FY17.

PANACEA BIOTECH Cash Flow Statement 2017-18

ParticularsNo. of months1212% Change
Year EndingMar-17Mar-18
Cash Flow from Operating ActivitiesRs m1,3071,180-9.7%
Cash Flow from Investing ActivitiesRs m-258553-
Cash Flow from Financing ActivitiesRs m-1,070-1,644-
Net Cash FlowRs m-2190-
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for PANACEA BIOTECH

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs -12.4, an decline from the EPS of Rs -6.7 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 171.2, stands at -6.3 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 4.9 times, while the price to sales ratio stands at 2.5 times.
  • The company's price to cash flow (P/CF) ratio stood at -59.3 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Sales per share (Unadj.)Rs88.896.8
TTM Earnings per shareRs-6.7-12.4
Diluted earnings per shareRs-6.7-12.4
Price to Cash Flow x39.1-59.3
TTM P/E ratiox-6.3-6.3
Price / Book Value ratiox2.34.9
Market CapRs m10,48610,486
Dividends per share (Unadj.)Rs0.00.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for PANACEA BIOTECH

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 0.8x during FY18, from 0.9x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 0.3x during FY18, from 0.4x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at -24.6% during FY18, from -11.5% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 3.9% during FY18, from 4.6% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 1.5% during FY18, from 3.3% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Current ratiox0.90.8
Debtors’ DaysDays9584
Interest coveragex0.40.3
Debt to equity ratiox2.01.8
Return on assets%3.31.5
Return on equity%-11.5-24.6
Return on capital employed%4.63.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how PANACEA BIOTECH has performed over the last 5 years, please visit here.

PANACEA BIOTECH Share Price Performance

Over the last one year, PANACEA BIOTECH share price has moved up from Rs 276.9 to Rs 171.2, registering a loss of Rs 105.7 or around 38.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,139.2 (down 0.4%). Over the last one year it has moved up from 13,308.8 to 14,139.2, a gain of 830 points (up 6.2%).

(To know more, check out historical annual results for PANACEA BIOTECH and quarterly results for PANACEA BIOTECH)

Equitymaster requests your view! Post a comment on "PANACEA BIOTECH 2017-18 Annual Report Analysis". Click here!

  

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - NOVARTIS COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS